Ipsen has made available Dysport (abobotulinumtoxinA) for the treatment of cervical dystonia in adults. Dysport was originally approved by the FDA on April 29, 2009 for two separate indications: the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain in both toxin-naive and previously treated patients, and the temporary improvement in the appearance of moderate to severe glabellar lines in adults <65 years of age. Ipsen will market Dysport in the United States for the indication of cervical dystonia, while Medicis already markets Dysport for the management of glabellar lines.

Dysport is a botulinum toxin type A that acts at the level of the neuromuscular junction in the targeted muscle and inhibits release of acetylcholine from peripheral cholinergic nerve endings to reduce muscular spasm.

For more information call (888) 525-2423 or visit www.Dysport.com.